Skip to main content

Table 3 Univariate analysis of prognostic factors for 170 patients with stage T3-4N1 NPC

From: Can neoadjuvant chemotherapy improve survival in stage T3-4N1 nasopharyngeal carcinoma? A propensity matched analysis

Variables

OS

LRFS

DRFS

RFS

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

Sex

(male vs. female)

0.904 (0.455–1.796)

0.774

0.968 (0.720–1.301)

0.828

0.784 (0.219–2.800)

0.708

0.893 (0.524–1.520)

0.676

Age

(years)

1.018 (0.974–1.064)

0.426

0.961 (0.919–1.006)

0.092

1.009 (0.956–1.065)

0.736

1.001 (0.969–1.035)

0.931

Smoking history

(yes vs. no)

3.595 (1.465–8.819)

0.005

1.379 (0.535–3.556)

0.506

2.073 (0.676–6.353)

0.202

2.333 (1.192–4.565)

0.013

Alcohol history

(yes vs. no)

0.485 (0.064–3.668)

0.483

0.587 (0.079–4.374)

0.603

0.909 (0.118–7.031)

0.927

0.297 (0.040–2.175)

0.232

Family of cancer

(yes vs. no)

0.848 (0.308–2.334)

0.749

0.756 (0.277–2.063)

0.585

1.102 (0.339–3.581)

0.871

0.966 (0.466–2.004)

0.927

T classification

(T3 vs. T4)

3.997 (1.633–9.782)

0.002

2.008 (0.810–4.980)

0.132

2.548 (0.833–7.800)

0.101

2.158 (1.080–4.313)

0.029

PLNC

(negative vs. positive)

3.038 (1.191–7.747)

0.020

1.975 (0.766–5.096)

0.159

4.522 (1.513–13.514)

0.007

3.132 (1.576–6.227)

0.001

Lymph node diameter

(mm, maximum, ≤15.0 vs. > 15.0)

2.546 (1.037–6.252)

0.041

2.617 (1.084–6.318)

0.032

2.532 (0.827–7.749)

0.104

2.335 (1.202–4.535)

0.012

Cervical lymph node

(yes vs. no)

1.007 (0.377–2.688)

0.989

1.294 (0.474–3.531)

0.615

0.605 (0.198–1.851)

0.378

0.840 (0.416–1.696)

0.627

EBV DNA

(copy/ml, < 2000 vs. ≥2000)

1.176 (0.483–2.864)

0.720

1.163 (0.490–2.760)

0.733

3.022 (0.831–10.993)

0.093

1.456 (0.742–2.856)

0.274

HGB

(g/L, < 113 vs. 113–151 vs. ≥151)

0.746 (0.305–1.826)

0.521

1.066 (0.465–2.442)

0.880

0.998 (0.342–2.913)

0.997

1.068 (0.565–2.017)

0.840

CRP

(g/ml, < 1.0 vs. 1.0–3.0 vs. ≥3.0)

1/366 (0.791–2.359)

0.263

1.204 (0.715–2.027)

0.484

0.644 (0.310–1.337)

0.238

1.215 (0.811–1.820)

0.345

LDH

(U/L, < 245 vs. ≥245)

0.045 (0–215.889)

0.473

0.692 (0.093–5.153)

0.719

0.045 (0–882.623)

0.538

0.406 (0.056–2.966)

0.374

NCT

(yes vs. no)

1.155 (0.476–2.801)

0.750

1.349 (0.568–3.201)

0.497

0.843 (0.283–2.510)

0.759

0.967 (0.502–1.862)

0.919

  1. Abbreviations: NPC Nasopharyngeal carcinoma; HR Hazard ratio; CI Confidence interval; NCT Neoadjuvant chemotherapy; PLNC Pretreatment lymph node condition; EBV Epstein–Barr virus; OS Overall survival; LRFS Locoregional recurrence-free survival; DRFS Distant recurrence-free survival; RFS Recurrence-free survival; HGB Hemoglobin; CRP C-reactive protein; LDH Lactate dehydrogenase
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us